Skip to content
Catalyst

pyridoxineWhat was measured

Measured, with no finding

2,534 endpoints

Show what was measuredHide what was measured
  • visual and myoclonic seizures after vitamin B6 withdrawal

    increases, n = 1

    At the age of 12 years 1 month, 2 months after withdrawal of vitamin B6, visual seizures began to occur frequently

    PMID 10210253 · one of two readings recorded this

  • RBC folate

    decreases

    The mean RBC folate concentration for patients taking diuretics (281.01 +/- 17.56 ng/mL) was significantly lower than the mean RBC folate concentration for patients not taking diuretics (430.85 +/- 28.58 ng/mL)

    PMID 10498160 · one of two readings recorded this

  • serum homocysteine

    increases

    The mean serum homocysteine concentration for patients taking diuretics (17.87 +/- 1.72 micromol/L) was significantly higher than the mean serum homocysteine concentration for patients not taking diuretics (10.31 +/- 0.99 micromol/L)

    PMID 10498160 · one of two readings recorded this

  • serum vitamin B6 and vitamin B12

    no effect

    Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups

    PMID 10498160 · one of two readings recorded this

  • serum vitamin B6 concentration in hypertensive patients on long-term diuretics versus not; diuretic is the exposure

    no effect, serum vitamin B6 not significantly different between diuretic and non-diuretic groups

    Not recorded as a finding: the compound is what was measured, not what was given

    Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups.

    PMID 10498160 · one of two readings recorded this

  • serum vitamin B6 concentration in hypertensive patients on long-term diuretics versus not on diuretics

    no effect

    Not recorded as a finding: the compound is what was measured, not what was given

    Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups.

    PMID 10498160 · one of two readings recorded this

  • incidence of dental decay in pregnant women, pyridoxine capsules or lozenges versus control

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Pyridoxine supplementation either as oral capsules (odds ratio 0.63, 95% confidence interval 0. 41 to 0.95) or lozenges (odds ratio 0.33, 95% confidence interval 0. 22-0.51) was associated with decreased incidence of dental decay in pregnant women.

    PMID 10796172 · one of two readings recorded this

  • incidence of dental decay in pregnant women

    decreases, n = 371

    or lozenges (odds ratio 0.33, 95% confidence interval 0. 22-0.51)

    PMID 10796172 · one of two readings recorded this

  • incidence of dental decay in pregnant women

    decreases, n = 371

    Pyridoxine supplementation either as oral capsules (odds ratio 0.63, 95% confidence interval 0. 41 to 0.95)

    PMID 10796172 · one of two readings recorded this

  • peripheral polyneuropathy symptom score (the authors' PPN symptom score) and predialysis serum pyridoxal-5'-phosphate in haemodialysis patients

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Nonetheless, it was demonstrated that supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P and dramatically attenuated PPN symptoms compared with initial symptoms.

    PMID 10978399 · one of two readings recorded this

  • PPN symptom score

    no effect

    No improvement was observed in response to vitamin B(12) supplementation

    PMID 10978399 · one of two readings recorded this

  • PPN symptom score

    decreases

    supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P and dramatically attenuated PPN symptoms compared with initial symptoms

    PMID 10978399 · one of two readings recorded this

  • predialysis serum P5P after supplementation

    increases

    supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P

    PMID 10978399 · one of two readings recorded this

  • predialysis serum P5P, PPN vs non-PPN patients

    no effect

    predialysis serum P5P levels of HD patients with PPN were not significantly lower than those of matched HD patients without PPN

    PMID 10978399 · one of two readings recorded this

  • PANSS scores (mental state)

    no effect, n = 15

    PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state

    PMID 11838627 · one of two readings recorded this

  • psychotic symptoms in schizophrenia, Positive and Negative Syndrome Scale (PANSS)

    no effect, no differences in PANSS between vitamin B6 and placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state.

    PMID 11838627 · one of two readings recorded this

  • psychotic symptoms on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia and schizoaffective patients

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state.

    PMID 11838627 · one of two readings recorded this

  • erythrocyte alanine and aspartate aminotransaminase activity coefficients

    no effect

    Erythrocyte alanine aminotransaminase activity coefficient and EAST-AC did not change significantly

    PMID 12001008 · one of two readings recorded this

  • mean vitamin B6 intake over study

    Patients had an adequate mean vitamin B6 intake (16.26+/-19.39 mg) during the 14 day study

    PMID 12001008 · one of two readings recorded this

  • plasma PLP and PL concentrations

    decreases, p = 0.05

    plasma PLP and PL concentrations significantly decreased at the 14th day after admission (P<0.05)

    PMID 12001008 · one of two readings recorded this

  • relationship of vitamin B6 intake and status indicators (plasma PLP, PL, urinary 4-PA, EALT-AC, EAST-AC) with APACHE II score, length of ICU and hospital stay and ventilation dependency in ventilated critically ill patients

    no effect

    Not recorded as a finding: no estimate is reported anywhere

    No significant relationships were found between APACHE II scores and clinical outcomes (the length of ICU and hospital stay, the length of ventilation dependency) of patients, vitamin B6 intake or status indicators.

    PMID 12001008 · one of two readings recorded this

  • urinary 4-pyridoxic acid

    increases, p = 0.001

    Urinary 4-PA significantly increased at the 14th day (P<0.001)

    PMID 12001008 · one of two readings recorded this

  • vitamin B6 intake, day 14 vs day 1

    increases, p = 0.001

    Mean vitamin B6 intake was significantly higher on day 14 than on day 1 (P<0.001)

    PMID 12001008 · one of two readings recorded this

  • PLP association with reticulocyte count

    decreases

    PLP concentration was associated positively with weight, body mass index, and arm circumference -scores and negatively with reticulocyte count

    PMID 12218594 · one of two readings recorded this

  • proportion with PLP below deficiency criterion

    Seventy-seven percent had a PLP concentration below the deficiency criterion (20 nmol/L) suggested by the Dietary Reference Intakes (1998)

    PMID 12218594 · one of two readings recorded this

  • serum pyridoxal 5-phosphate (PLP) concentration

    The PLP concentration of subjects with SCD-SS was 15.6 +/- 15.2 nmol/L

    PMID 12218594 · one of two readings recorded this

  • urinary 4-pyridoxic acid

    decreases

    Urinary 4-PA was lower in children with SCD-SS versus controls, although 4-PA/creatinine values did not differ between groups

    PMID 12218594 · one of two readings recorded this

  • vitamin B6 status in children with sickle cell disease-SS, serum pyridoxal 5-phosphate and urinary 4-pyridoxic acid

    Not recorded as a finding: the compound is what was measured, not what was given

    Seventy-seven percent had a PLP concentration below the deficiency criterion (20 nmol/L) suggested by the Dietary Reference Intakes (1998).

    PMID 12218594 · one of two readings recorded this

  • plasma 4-PA increase after vitamin B6

    increases

    Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively

    PMID 12507972 · one of two readings recorded this

  • plasma 4-PA intraindividual variation

    During the 84-day study period, the intraindividual variation (CV) in patients not treated with vitamin B(6) (groups B and D) was 45% for PLP and 67% for 4-PA

    PMID 12507972 · one of two readings recorded this

  • plasma B6 vitamer concentrations (pyridoxal 5'-phosphate, pyridoxal, 4-pyridoxic acid) before and after oral vitamin B6

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively.

    PMID 12507972 · one of two readings recorded this

  • plasma B6 vitamers, later time points

    no effect

    No significant additional increase was observed at the later time points

    PMID 12507972 · one of two readings recorded this

  • plasma PL increase after vitamin B6

    increases

    Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively

    PMID 12507972 · one of two readings recorded this

  • plasma PLP increase after vitamin B6

    increases

    Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively

    PMID 12507972 · one of two readings recorded this

  • plasma PLP intraindividual variation

    During the 84-day study period, the intraindividual variation (CV) in patients not treated with vitamin B(6) (groups B and D) was 45% for PLP and 67% for 4-PA

    PMID 12507972 · one of two readings recorded this

  • breast cancer risk by plasma vitamin B6 (pyridoxal phosphate) quintile, nested case-control

    RR 0.70, 95% CI 0.48 to 1.02 highest vs lowest quintile

    Not recorded as a finding: a direction is stated and the estimate does not support it

    The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09).

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk by plasma vitamin B6 quintile, nested case-control, Nurses' Health Study

    decreases, multivariable RR 0.70, 95% CI = 0.48 to 1.02; P(trend) = .09, p = 0.09

    Not recorded as a finding: a direction is stated and the estimate does not support it

    The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09).

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    decreases, p = 0.06

    The multivariable RR comparing women in the highest quintile of plasma folate with those in the lowest was 0.73 (95% confidence interval [CI] = 0.50 to 1.07; P(trend) =.06)

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    no effect

    Plasma homocysteine was not associated with breast cancer risk

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    decreases, p = 0.09

    The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09)

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    decreases

    among women consuming at least 15 g/day (i.e., approximately 1 drink/day) of alcohol (multivariable RR = 0.11, 95% CI = 0.02 to 0.59 for highest versus lowest quintile)

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    decreases

    in contrast with that of women consuming less than 15 g/day (multivariable RR = 0.72, 95% CI = 0.49 to 1.05)

    PMID 12618502 · one of two readings recorded this

  • breast cancer risk

    decreases

    Plasma vitamin B(12) levels were inversely associated with breast cancer risk among premenopausal women (multivariable RR = 0.36, 95% CI = 0.15 to 0.86 for highest versus lowest quintile)

    PMID 12618502 · one of two readings recorded this

  • ischemic stroke or transient ischemic attack case-control status by low plasma pyridoxal 5'-phosphate; endogenous PLP level, nobody dosed

    increases, adjusted OR 4.6, 95% CI 1.4 to 15.1 for low PLP

    Not recorded as a finding: another reason, stated per paper

    After stroke risk factors were controlled for, a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001) but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1).

    PMID 12738890 · one of two readings recorded this

  • ischemic stroke/TIA case status by fasting plasma pyridoxal 5'-phosphate, case-control

    increases, low PLP adjusted OR 4.6, 95% CI 1.4 to 15.1

    Not recorded as a finding: another reason, stated per paper

    After stroke risk factors were controlled for, a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001) but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1).

    PMID 12738890 · one of two readings recorded this

  • mean plasma pyridoxal 5'-phosphate (PLP)

    decreases, p = 0.0001

    Mean PLP was significantly lower in cases than controls (39.97 versus 84.1 nmol/L, P<0.0001)

    PMID 12738890 · one of two readings recorded this

  • stroke/TIA risk associated with elevated tHcy

    no effect

    but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1)

    PMID 12738890 · one of two readings recorded this

  • stroke/TIA risk associated with low PLP

    increases, p = 0.001

    a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001)

    PMID 12738890 · one of two readings recorded this

  • association of tHcy with education, CDR, MMSE, blood lipids, albumin or ApoE genotype

    no effect, p = 0.15

    tHcy levels were not related in AD patients or controls to education, CDR, MMSE, blood lipids, albumin or ApoE genotype (p>0.15)

    PMID 12766793 · one of two readings recorded this

  • correlation of plasma tHcy with triglyceride levels

    decreases, p = 0.023

    There was a negative correlation between plasma tHcy and triglyceride levels in AD patients (p=0.023), but not in controls

    PMID 12766793 · one of two readings recorded this

  • dietary folate intake after age 60

    decreases, p = 0.001

    AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls

    PMID 12766793 · one of two readings recorded this

  • dietary vitamin B6 intake after age 60 in Alzheimer's disease patients versus matched controls, by questionnaire

    decreases, AD patients consumed less dietary vitamin B6 than controls, p=0.05, p = 0.05

    Not recorded as a finding: the compound is what was measured, not what was given

    AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls.

    PMID 12766793 · one of two readings recorded this

  • dietary vitamin B6 intake after age 60

    decreases, p = 0.05

    AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls

    PMID 12766793 · one of two readings recorded this

  • estimated daily dietary vitamin B6 intake after age 60 in Alzheimer's disease patients versus matched controls, from a food frequency questionnaire

    decreases, p = 0.05

    Not recorded as a finding: the compound is what was measured, not what was given

    AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls.

    PMID 12766793 · one of two readings recorded this

  • plasma total homocysteine

    no effect, p = 0.25

    tHcy did not differ significantly between controls (11.5 +/- 3.7 mmol/L) and AD patients (12.3 +/- 4.3 mmol/L)(p=0.25)

    PMID 12766793 · one of two readings recorded this

  • cognition and mood

    no effect

    No statistically significant differences between treatment and placebo were found in their effects on cognition or mood

    PMID 14584010 · one of two readings recorded this

  • cognition or mood in healthy older people, vitamin B6 versus placebo (instrument not named in the abstract)

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    No statistically significant differences between treatment and placebo were found in their effects on cognition or mood.

    PMID 14584010 · one of two readings recorded this

  • erythrocyte aspartate aminotransferase activity (vitamin B6 status)

    increases, p = 0.00001

    erythrocyte enzyme asparate aminotransferase (WMD 0.43, 95%CI 0.30 to 0.56, P<0.00001)

    PMID 14584010 · one of two readings recorded this

  • mood and cognition

    no effect

    No statistically significant benefits from vitamin B6 on mood or cognition were observed

    PMID 14584010 · one of two readings recorded this

  • plasma pyridoxal-5'-phosphate (blood vitamin B6 activity)

    increases, p = 0.00001

    increased blood vitamin B6 activity as assessed as by plasma pyridoxal-5'-phosphate (WMD 238, 95%CI 211.58 to 264.42, P<0.00001)

    PMID 14584010 · one of two readings recorded this

  • electrophoretic mobility of peripheral blood lymphocytes and cellular immunity

    increases

    A favourable effect was found of daily oral administration of 50 mg pyridoxine on electrophoretic mobility of peripheral blood lymphocytes and cellular immunity

    PMID 1459821 · one of two readings recorded this

  • erythrocyte vitamin B6

    no effect

    Haemodialysis and charcoal haemoperfusion have led to non-significant decrease of erythrocyte vitamin B6

    PMID 1459821 · one of two readings recorded this

  • prevention of vitamin B6 deficiency

    decreases

    long-term daily oral supplementation of 6 mg vitamin B6 was sufficient for prevention of vitamin B6 deficiency in chronic renal failure

    PMID 1459821 · one of two readings recorded this

  • nausea score change, ginger vs vitamin B6

    no effect, p = 0.136

    The mean score change after treatment with ginger was 1.4 (2.21), less than with vitamin B6, which was 2.0 (2.19) but with no statistically significant difference (95% CI -1.4 to 0.2, p = 0.136)

    PMID 14649969 · one of two readings recorded this

  • nausea score on visual analogue scale and number of vomiting episodes in nausea and vomiting of pregnancy

    no effect, no significant difference between ginger and vitamin B6 in nausea score change (95% CI -1.4 to 0.2), p = 0.136

    Not recorded as a finding: the comparison was against another active treatment

    The mean score change after treatment with ginger was 1.4 (2.21), less than with vitamin B6, which was 2.0 (2.19) but with no statistically significant difference (95% CI -1.4 to 0.2, p = 0.136).

    PMID 14649969 · one of two readings recorded this

  • nausea score (VAS), ginger arm

    decreases, p = 0.001

    The ginger and vitamin B6 significantly reduced the nausea scores from 5.0 (SD, 1.99) to 3.6 (SD, 2.48) and 5.3 (SD, 2.08) to 3.3 (SD, 2.07) respectively, with p < 0.001

    PMID 14649969 · one of two readings recorded this

  • nausea score (VAS), vitamin B6 arm

    decreases, p = 0.001

    The ginger and vitamin B6 significantly reduced the nausea scores from 5.0 (SD, 1.99) to 3.6 (SD, 2.48) and 5.3 (SD, 2.08) to 3.3 (SD, 2.07) respectively, with p < 0.001

    PMID 14649969 · one of two readings recorded this

  • vomiting episodes change, ginger vs vitamin B6

    no effect, p = 0.498

    The mean number change after treatment with ginger was 0.7 (2.18), more than with vitamin B6, which was 0.5 (1.44) but with no statistically significant difference, (p = 0.498)

    PMID 14649969 · one of two readings recorded this

  • vomiting episodes in previous 24 hours, ginger arm

    decreases, p = 0.01

    The ginger and vitamin B6 also significantly reduced the number of vomiting episodes from 1.9 (2.06) to 1.2 (1.75) and 1.7 (1.81) to 1.2 (1.50) respectively, with p < 0.01

    PMID 14649969 · one of two readings recorded this

  • vomiting episodes in previous 24 hours, vitamin B6 arm

    decreases, p = 0.01

    The ginger and vitamin B6 also significantly reduced the number of vomiting episodes from 1.9 (2.06) to 1.2 (1.75) and 1.7 (1.81) to 1.2 (1.50) respectively, with p < 0.01

    PMID 14649969 · one of two readings recorded this

  • incident hemorrhagic stroke

    no effect

    intake of folate was associated with a significantly lower risk of ischemic but not hemorrhagic stroke

    PMID 14671243 · one of two readings recorded this

  • incident ischemic stroke

    decreases, p = 0.05

    The multivariate relative risk of ischemic stroke was 0.71 (95% CI, 0.52 to 0.96; P for trend=0.05) for men in the highest quintile of intake compared with those who in the lowest quintile

    PMID 14671243 · one of two readings recorded this

  • incident ischemic stroke

    decreases

    Intake of vitamin B12, but not B6, was also inversely associated with risk of ischemic stroke

    PMID 14671243 · one of two readings recorded this

  • incident ischemic stroke

    no effect

    Intake of vitamin B12, but not B6, was also inversely associated with risk of ischemic stroke

    PMID 14671243 · one of two readings recorded this

  • daily folate intake

    decreases

    Daily folate intake was significantly lower in case subjects (mean, 288; 95% confidence interval [CI], 266-309 microg) than in control subjects (324; 95% CI, 313-335 microg)

    PMID 14981440 · one of two readings recorded this

  • daily vitamin B6 intake

    decreases

    Daily vitamin B6 intake was also lower in case subjects (2.05; 95% CI, 1.92-2.19 mg versus 2.26; 95% CI, 2.19-2.33 mg)

    PMID 14981440 · one of two readings recorded this

  • peripheral arterial occlusive disease, ankle-brachial pressure index < 0.9, by dietary vitamin B6 intake

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%.

    PMID 14981440 · one of two readings recorded this

  • peripheral arterial occlusive disease defined as ankle-brachial pressure index < 0.9, by daily dietary vitamin B6 intake (EPIC food frequency questionnaire)

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%.

    PMID 14981440 · one of two readings recorded this

  • prevalence of peripheral arterial occlusive disease (ABPI < 0.9)

    PAOD, defined as an ankle-brachial pressure index (ABPI) < 0.9, was present in 86 (22%) of subjects

    PMID 14981440 · one of two readings recorded this

  • risk of PAOD per 1 standard deviation increase in folate intake

    decreases

    This model suggests that increasing daily folate intake by 1 standard deviation decreased the risk of PAOD by 46%

    PMID 14981440 · one of two readings recorded this

  • risk of PAOD per 1 standard deviation increase in vitamin B6 intake

    decreases

    A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%

    PMID 14981440 · one of two readings recorded this

  • correlation of Hcy level with left atrial diameter

    increases, p = 0.001

    A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001)

    PMID 15389232 · one of two readings recorded this

  • ischemic complications during NVAF

    increases

    elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95% CI 1.15-6.20)

    PMID 15389232 · one of two readings recorded this

  • nonvalvular atrial fibrillation

    increases

    Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46

    PMID 15389232 · one of two readings recorded this

  • nonvalvular atrial fibrillation

    increases

    vitamin B6: OR 3.02, 95% CI 1.02-8.95

    PMID 15389232 · one of two readings recorded this

  • presence of nonvalvular atrial fibrillation in patients on oral anticoagulants versus controls, by plasma vitamin B6 quartile (case-control, not incident AF)

    increases, vitamin B6 deficiency (lowest quartile) OR 3.02, 95% CI 1.02-8.95

    Not recorded as a finding: this platform holds no node for the endpoint

    Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95).

    PMID 15389232 · one of two readings recorded this

  • presence of nonvalvular atrial fibrillation in patients versus controls by plasma vitamin B6 status (lowest quartile)

    increases, vitamin B6 deficiency OR 3.02, 95% CI 1.02-8.95

    Not recorded as a finding: this platform holds no node for the endpoint

    Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95).

    PMID 15389232 · one of two readings recorded this

  • acute neuroleptic-induced akathisia severity, Barnes Akathisia Scale (BAS) subscales

    increases, at least 2-point BAS global reduction in 8 patients (80%) with vitamin B6 vs 3 (30%) placebo, p = 0.037

    Not recorded as a finding: this platform holds no node for the endpoint

    A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037).

    PMID 15554771 · one of two readings recorded this

  • Barnes Akathisia Scale global subscale

    decreases, p = 0.004, n = 20

    The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS

    PMID 15554771 · one of two readings recorded this

  • Barnes Akathisia Scale objective subscale

    no effect, p = 0.079, n = 20

    The objective subscale did not demonstrate significant positive results (p = .079)

    PMID 15554771 · one of two readings recorded this

  • Barnes Akathisia Scale subjective-awareness of restlessness subscale

    decreases, p = 0.0004, n = 20

    The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS

    PMID 15554771 · one of two readings recorded this

  • Barnes Akathisia Scale subjective-distress subscale

    decreases, p = 0.01, n = 20

    The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS

    PMID 15554771 · one of two readings recorded this

  • responders, reduction of at least 2 points on BAS global subscale

    p = 0.037, n = 20

    A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037)

    PMID 15554771 · one of two readings recorded this

  • responders, reduction of at least 2 points on BAS global subscale

    decreases, p = 0.037, n = 20

    A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037)

    PMID 15554771 · one of two readings recorded this

  • albumin concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • albumin concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • methionine-homocysteine flux rates (transmethylation, remethylation, transsulfuration)

    no effect

    No significant changes in flux rates were observed

    PMID 15671107 · one of two readings recorded this

  • plasma homocysteine concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • plasma homocysteine concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • plasma vitamin B6 concentration after oral estradiol in postmenopausal women

    decreases, vitamin B6 decreased 25% with estradiol and 38% with estradiol plus dydrogesterone

    Not recorded as a finding: the compound is what was measured, not what was given

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%).

    PMID 15671107 · one of two readings recorded this

  • vitamin B6 concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • vitamin B6 concentration, mean change from baseline vs placebo

    decreases

    The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)

    PMID 15671107 · one of two readings recorded this

  • advanced distal colorectal adenoma risk

    decreases, p = 0.08

    RR = 0.65, 95% CI = 0.37 to 1.11; P(trend) = .08

    PMID 15870439 · one of two readings recorded this

  • colon cancer risk

    decreases, p = 0.02

    RR = 0.42, 95% CI = 0.21 to 0.85; P(trend) = .02

    PMID 15870439 · one of two readings recorded this

  • colon cancer risk

    decreases, p = 0.01

    for colon cancer, RR = 0.38, 95% CI = 0.18 to 0.80; P(trend) = .01

    PMID 15870439 · one of two readings recorded this

  • colon cancer risk

    decreases, p = 0.007

    RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007

    PMID 15870439 · one of two readings recorded this

  • colorectal cancer risk

    decreases, p = 0.07

    RR = 0.56, 95% CI = 0.31 to 1.01; P(trend) = .07

    PMID 15870439 · one of two readings recorded this

  • colorectal cancer risk

    decreases, p = 0.03

    for colorectal cancer, RR = 0.48, 95% CI = 0.25 to 0.92; P(trend) = .03

    PMID 15870439 · one of two readings recorded this

  • early-stage colorectal adenoma risk

    no effect, p = 0.52

    RR = 0.85, 95% CI = 0.52 to 1.38; P(trend) = .52

    PMID 15870439 · one of two readings recorded this

  • plasma pyridoxal 5'-phosphate concentration and total vitamin B6 intake in relation to colon cancer risk, nested case-control, Nurses' Health Study

    decreases, RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Total vitamin B(6) intake was also statistically significantly inversely associated with colon cancer risk (RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007).

    PMID 15870439 · one of two readings recorded this

  • risk of colon cancer by total vitamin B6 intake; colorectal cancer and adenoma by plasma pyridoxal 5'-phosphate quartile, nested case-control

    decreases, RR = 0.51, 95% CI = 0.27 to 0.97 for total vitamin B6 intake and colon cancer

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Total vitamin B(6) intake was also statistically significantly inversely associated with colon cancer risk (RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007).

    PMID 15870439 · one of two readings recorded this

  • colorectal cancer risk, trend across vitamin B6 intake

    decreases, p = 0.002

    long-term intake of dietary vitamin B6 was significantly inversely associated with risk of colorectal cancer (P value for trend = .002)

    PMID 15940618 · one of two readings recorded this

  • colorectal cancer risk

    decreases

    those in the highest quintile had a 34% lower risk (multivariate rate ratio, 0.66; 95% confidence interval, 0.50-0.86)

    PMID 15940618 · one of two readings recorded this

  • colorectal cancer risk

    decreases

    The multivariate rate ratio of colorectal cancer comparing extreme quintiles of vitamin B6 intake was 0.28 (95% confidence interval, 0.13-0.59) among women who consumed > or = 30 g/wk of alcohol

    PMID 15940618 · one of two readings recorded this

  • adequacy of thiamin status

    unclear

    Although B1 intake of greater than or equal to 1.0 mg/day was adequate for maintenance of normal thiamin status in most subjects of this study

    PMID 1619179 · one of two readings recorded this

  • EALT indices sensitivity to B6 intake versus EAST indices

    unclear

    Although the EALT-indices were more sensitive to changes in B6 intake than the EAST-indices, the EASTBA and SA correlated most consistently with the intake

    PMID 1619179 · one of two readings recorded this

  • erythrocyte alanine and aspartate aminotransferase apoenzyme levels

    decreases

    Both alanine (EALT) and aspartate (EAST) aminotransferase apoenzyme levels declined and AC values increased significantly during the first 3 months

    PMID 1619179 · one of two readings recorded this

  • erythrocyte aminotransferase activity coefficients

    increases

    Both alanine (EALT) and aspartate (EAST) aminotransferase apoenzyme levels declined and AC values increased significantly during the first 3 months

    PMID 1619179 · one of two readings recorded this

  • erythrocyte transketolase activities and activity coefficients correlation with B1 intake

    unclear

    Postoperative erythrocyte transketolase basal (BA) and thiamin pyrophosphate-stimulated (SA) activities and activity coefficients (AC) correlated significantly with B1 intake

    PMID 1619179 · one of two readings recorded this

  • maintenance of coenzyme saturation of erythrocyte aminotransferases

    no effect

    Vitamin B6 intake at the current recommended dietary allowance (1.6 mg) was not adequate to maintain coenzyme saturation of the erythrocyte aminotransferases

    PMID 1619179 · one of two readings recorded this

  • 24 h urinary xanthurenic acid (XA) excretion after tryptophan load

    modulates

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion

    PMID 16277693 · one of two readings recorded this

  • Erythrocyte aspartate aminotransferase activity coefficient (alphaEAST)

    modulates

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion

    PMID 16277693 · one of two readings recorded this

  • Erythrocyte pyridoxal 5'-phosphate concentration

    increases

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion

    PMID 16277693 · one of two readings recorded this

  • plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte aspartate aminotransferase activity coefficient (alphaEAST), urinary 4-pyridoxic acid and xanthurenic acid excretion; TNF-alpha and IL-6 production

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion.

    PMID 16277693 · one of two readings recorded this

  • Plasma pyridoxal 5'-phosphate concentration

    increases

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion

    PMID 16277693 · one of two readings recorded this

  • Post-methionine load net homocysteine increase (DeltatHcy)

    decreases, p = 0.09

    Pyridoxine supplementation also showed a trend (p < 0.09) towards a reduction in post-methionine load DeltatHcy

    PMID 16277693 · one of two readings recorded this

  • Pro-inflammatory cytokine production (TNF-alpha, IL-6)

    no effect

    Supplementation did not affect pro-inflammatory cytokine production

    PMID 16277693 · one of two readings recorded this

  • pro-inflammatory cytokine (TNF-alpha and IL-6) production before and after 50 mg/day pyridoxine for 30 days vs placebo in rheumatoid arthritis; CRP and ESR also examined but no result stated in the abstract

    no effect, supplementation did not affect pro-inflammatory cytokine production

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Supplementation did not affect pro-inflammatory cytokine production.

    PMID 16277693 · one of two readings recorded this

  • Urinary 4-pyridoxic acid (4-PA) excretion

    increases

    Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion

    PMID 16277693 · one of two readings recorded this

  • Colorectal cancer risk, dietary folate and vitamin B6 intake

    decreases

    dietary intakes of folate and vitamin B(6) were significantly inversely associated with colorectal cancer risk among women who were not taking supplements containing folate and vitamin B(6)

    PMID 16339055 · one of two readings recorded this

  • Colorectal cancer risk, dietary folate intake

    decreases

    0.46 (95% CI: 0.26, 0.81) for dietary folate

    PMID 16339055 · one of two readings recorded this

  • Colorectal cancer risk, dietary vitamin B6 intake

    no effect

    0.69 (95% CI: 0.41, 1.15) for dietary vitamin B(6)

    PMID 16339055 · one of two readings recorded this

  • Colorectal cancer risk, multivitamin supplement use

    no effect

    The use of multivitamin supplements was not related to colorectal cancer risk

    PMID 16339055 · one of two readings recorded this

  • Colorectal cancer risk, total folate intake

    no effect

    1.16 (95% confidence interval (CI): 0.76, 1.79) for total folate

    PMID 16339055 · one of two readings recorded this

  • Colorectal cancer risk, total vitamin B6 intake

    no effect

    1.14 (95% CI: 0.77, 1.69) for total vitamin B(6)

    PMID 16339055 · one of two readings recorded this

  • colorectal cancer risk

    unclear

    Although folate intake was inversely associated with colorectal cancer, this association was attenuated after further controlling for dietary fiber intake

    PMID 16351505 · one of two readings recorded this

  • colorectal cancer risk

    no effect

    Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer

    PMID 16351505 · one of two readings recorded this

  • colorectal cancer risk

    no effect

    Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer

    PMID 16351505 · one of two readings recorded this

  • colorectal cancer risk

    no effect

    Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer

    PMID 16351505 · one of two readings recorded this

  • blood folic acid

    decreases

    Patients receiving phenytoin had significantly lower folic acid levels

    PMID 16414291 · one of two readings recorded this

  • blood homocysteine

    no effect

    No difference in homocysteine concentrations was observed among epileptic patients in terms of the anti-epileptic drug used

    PMID 16414291 · one of two readings recorded this

  • blood homocysteine

    increases

    Compared to the control group, epileptic patients on anti-epileptic drug had higher blood levels of homocysteine

    PMID 16414291 · one of two readings recorded this

  • blood homocysteine

    no effect

    Because there was no significant change in homocysteine concentrations in epileptic patients who were not receiving an anti-epileptic drug

    PMID 16414291 · one of two readings recorded this

  • blood pyridoxal 5'-phosphate (active circulating form of vitamin B6) in epileptic patients on anti-epileptic drugs versus other patients

    decreases

    Not recorded as a finding: the compound is what was measured, not what was given

    Patients receiving phenytoin had significantly lower folic acid levels and those receiving carbamazepine had marginally lower pyridoxal 5'-phosphate levels in comparison with those using other anti-epileptic drugs.

    PMID 16414291 · one of two readings recorded this

  • blood pyridoxal 5'-phosphate

    decreases

    those receiving carbamazepine had marginally lower pyridoxal 5'-phosphate levels in comparison with those using other anti-epileptic drugs

    PMID 16414291 · one of two readings recorded this

  • correlation of homocysteine with folic acid concentration

    decreases

    A negative correlation between homocysteine and folic acid concentrations was detected in epileptic patients on anti-epileptic drug

    PMID 16414291 · one of two readings recorded this

  • folic acid level versus duration of anti-epileptic drug use

    decreases

    The duration of anti-epileptic drug use was correlated to the decrease of folic acid levels, but not with changes observed in homocysteine, Vitamin B12 and pyridoxal 5'-phosphate levels

    PMID 16414291 · one of two readings recorded this

  • homocysteine level versus seizure frequency

    no effect

    No relationship between seizure frequency and homocysteine levels was observed in epileptic patients

    PMID 16414291 · one of two readings recorded this

  • pyridoxal 5'-phosphate level versus duration of anti-epileptic drug use

    no effect

    The duration of anti-epileptic drug use was correlated to the decrease of folic acid levels, but not with changes observed in homocysteine, Vitamin B12 and pyridoxal 5'-phosphate levels

    PMID 16414291 · one of two readings recorded this

  • acute neuroleptic-induced akathisia severity, Barnes Akathisia Rating Scale global subscale

    increases, at least 2-point BARS global reduction in 13/23 (56%) with vitamin B6 vs 1/17 (6%) placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005).

    PMID 16614537 · one of two readings recorded this

  • Barnes Akathisia Rating Scale global subscale

    decreases, p = 0.0001

    Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales

    PMID 16614537 · one of two readings recorded this

  • Barnes Akathisia Rating Scale objective subscale

    no effect, p = 0.056

    The objective subscale did not show significant positive results (P = 0.056)

    PMID 16614537 · one of two readings recorded this

  • Barnes Akathisia Rating Scale subjective distress subscale

    decreases, p = 0.0001

    Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales

    PMID 16614537 · one of two readings recorded this

  • Barnes Akathisia Rating Scale subjective subscale

    decreases, p = 0.0001

    Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales

    PMID 16614537 · one of two readings recorded this

  • responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale

    decreases, p = 0.0005, n = 20

    A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)

    PMID 16614537 · one of two readings recorded this

  • responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale

    p = 0.0005, n = 17

    A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)

    PMID 16614537 · one of two readings recorded this

  • responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale

    decreases, p = 0.0005, n = 23

    A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)

    PMID 16614537 · one of two readings recorded this

  • Apgar scores and breastmilk production

    no effect, n = 24

    between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour

    PMID 16625530 · one of two readings recorded this

  • Apgar scores and breastmilk production

    no effect, n = 24

    between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour

    PMID 16625530 · one of two readings recorded this

  • Apgar scores at one and five minutes after oral or intramuscular loading dose of pyridoxine at labour

    no effect

    Not recorded as a finding: no_outcome_node: no node for Apgar score

    No differences were found in Apgar scores at one or five minutes, or breastmilk production between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour.

    PMID 16625530 · one of two readings recorded this

  • dental decay in pregnant women, vitamin B6 capsules or lozenges

    decreases, capsules RR 0.84, 95% CI 0.71 to 0.98; lozenges RR 0.68, 95% CI 0.56 to 0.83

    Not recorded as a finding: no_outcome_node: no node for dental decay

    Vitamin B6 as oral capsules or lozenges resulted in decreased risk of dental decay in pregnant women (capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371; lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342).

    PMID 16625530 · one of two readings recorded this

  • dental decay risk in pregnant women, incidence of decay (capsules and lozenges)

    decreases, capsules RR 0.84, 95% CI 0.71 to 0.98; lozenges RR 0.68, 95% CI 0.56 to 0.83

    Not recorded as a finding: no_outcome_node: dental caries incidence has no entry in the outcome list

    Vitamin B6 as oral capsules or lozenges resulted in decreased risk of dental decay in pregnant women (capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371; lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342).

    PMID 16625530 · one of two readings recorded this

  • dental decay risk

    decreases, n = 342

    lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342

    PMID 16625530 · one of two readings recorded this

  • dental decay risk

    decreases, n = 371

    capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371

    PMID 16625530 · one of two readings recorded this

  • eclampsia risk

    no effect, n = 1242

    We did not find any statistically significant differences in the risk of eclampsia (capsules: n = 1242; three trials; lozenges: n = 944; one trial)

    PMID 16625530 · one of two readings recorded this

  • eclampsia risk

    no effect, n = 944

    We did not find any statistically significant differences in the risk of eclampsia (capsules: n = 1242; three trials; lozenges: n = 944; one trial)

    PMID 16625530 · one of two readings recorded this

  • low Apgar score at one minute

    no effect, n = 45

    low Apgar scores at one minute (oral pyridoxine: n = 45; one trial)

    PMID 16625530 · one of two readings recorded this

  • mean birthweight

    decreases, n = 33

    A small trial showed reduced mean birthweights with vitamin B6 supplementation (weighted mean difference -0.23 kg; 95% CI -0.42 to -0.04; n = 33; one trial)

    PMID 16625530 · one of two readings recorded this

  • pre-eclampsia risk

    no effect, n = 1197

    pre-eclampsia (capsules n = 1197; two trials; lozenges: n = 944; one trial)

    PMID 16625530 · one of two readings recorded this

  • pre-eclampsia risk

    no effect, n = 944

    pre-eclampsia (capsules n = 1197; two trials; lozenges: n = 944; one trial)

    PMID 16625530 · one of two readings recorded this

  • immune responses (white blood cell, neutrophils, lymphocyte subsets)

    no effect

    There were no significant changes with respect to immune responses in the control group over 14 days

    PMID 16670691 · one of two readings recorded this

  • plasma 4-pyridoxic acid (4-PA)

    increases

    Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups

    PMID 16670691 · one of two readings recorded this

  • plasma pyridoxal 5'-phosphate (PLP)

    increases

    Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups

    PMID 16670691 · one of two readings recorded this

  • plasma pyridoxal (PL)

    increases

    Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups

    PMID 16670691 · one of two readings recorded this

  • T-helper (CD4) cell number

    increases

    Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day

    PMID 16670691 · one of two readings recorded this

  • T-helper (CD4) cell number

    increases

    T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group

    PMID 16670691 · one of two readings recorded this

  • T-lymphocyte (CD3) number

    increases

    T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group

    PMID 16670691 · one of two readings recorded this

  • T-lymphocyte (CD3), T-helper (CD4) and T-suppressor (CD8) cell numbers and percentages, total lymphocyte count in ICU patients

    increases, significant increase on day 14 within the B6-50 group

    Not recorded as a finding: the result compares a group with itself, not with a control

    T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group.

    PMID 16670691 · one of two readings recorded this

  • T-lymphocyte percentage

    increases

    Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day

    PMID 16670691 · one of two readings recorded this

  • T-suppressor (CD8) cell number

    increases

    Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day

    PMID 16670691 · one of two readings recorded this

  • T-suppressor (CD8) cell percentage

    increases

    Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day

    PMID 16670691 · one of two readings recorded this

  • T-suppressor (CD8) cell percentage

    increases

    T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group

    PMID 16670691 · one of two readings recorded this

  • total lymphocyte count (TLC)

    increases

    Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day

    PMID 16670691 · one of two readings recorded this

  • urinary 4-pyridoxic acid (4-PA)

    increases

    Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups

    PMID 16670691 · one of two readings recorded this

  • flow-mediated dilation, brachial artery

    increases, n = 35

    This improvement in flow-mediated dilation occurred within 2 hours and was maintained at 8 weeks for each treatment

    PMID 16818571 · one of two readings recorded this

  • flow-mediated dilation, brachial artery

    increases

    and with folate/vitamin B6 from 2.8% +/- 3.5% to 10.5% +/- 4.4%

    PMID 16818571 · one of two readings recorded this

  • flow-mediated dilation, brachial artery

    increases

    flow-mediated dilation improved with folate from 2.6% +/- 4.3% (mean +/- SD) to 9.7% +/- 6.0%

    PMID 16818571 · one of two readings recorded this

  • flow-mediated dilation, brachial artery

    no effect

    Flow-mediated dilation in the placebo group, and glyceryltrinitrate-induced dilation in all groups, did not change

    PMID 16818571 · one of two readings recorded this

  • flow-mediated dilation, brachial artery

    increases

    with vitamin B6 from 3.5% +/- 4.0% to 8.3% +/- 4.2%

    PMID 16818571 · one of two readings recorded this

  • glyceryltrinitrate-induced dilation, brachial artery

    no effect

    Flow-mediated dilation in the placebo group, and glyceryltrinitrate-induced dilation in all groups, did not change

    PMID 16818571 · one of two readings recorded this

  • incident Parkinson disease

    no effect

    No association was observed for dietary folate and vitamin B(12)

    PMID 16864826 · one of two readings recorded this

  • incident Parkinson disease

    no effect

    No association was observed for dietary folate and vitamin B(12)

    PMID 16864826 · one of two readings recorded this

  • incident Parkinson disease

    decreases

    for highest vs lowest tertile, 0.46 [0.22 to 0.96]

    PMID 16864826 · one of two readings recorded this

  • incident Parkinson disease

    decreases

    hazard ratio per SD, 0.69 [95% CI 0.50 to 0.96]

    PMID 16864826 · one of two readings recorded this

  • incident Parkinson disease

    decreases

    Stratified analyses showed that this association was restricted to smokers

    PMID 16864826 · one of two readings recorded this

  • incident exocrine pancreatic cancer cases

    n = 81922

    During a mean follow-up of 7.2 years, through June 2005, 147 incident cases of pancreatic cancer were diagnosed

    PMID 17241865 · one of two readings recorded this

  • pancreatic cancer incidence, dietary or total vitamin B6 intake

    no effect

    whereas no significant association was observed for dietary or total vitamin B(6) intake

    PMID 17241865 · one of two readings recorded this

  • pancreatic cancer incidence, methionine intake highest vs lowest quartile

    decreases, p = 0.0005

    were 0.44 (95% CI, 0.26-0.73; P for trend = .0005) in women and men combined

    PMID 17241865 · one of two readings recorded this

  • pancreatic cancer incidence, methionine intake highest vs lowest quartile

    decreases, p = 0.002

    0.32 (95% CI, 0.15-0.65; P for trend = .002) in men

    PMID 17241865 · one of two readings recorded this

  • pancreatic cancer incidence, methionine intake highest vs lowest quartile

    no effect, p = 0.07

    0.59 (95% CI, 0.28-1.21; P for trend = .07) in women

    PMID 17241865 · one of two readings recorded this

The whole record — 2,534 rows